Latest News

ESMO E-Learning and V-Learning

Watch E-Learning and V-Learning webcasts produced by leading oncology experts and take the CME test.
Our open library offers over 80 modules!

view detailsof ESMO E-Learning and V-Learning

Breast Cancer - Basic Principles in the Management and Treatment (of cancer) - Personalised/Precision Medicine - Therapy - Anticancer Agents - Complications/Toxicities of Treatment

Add-On Taselisib Boosts ORR In ER-Positive Early-Stage Breast Cancer

  • 14 Aug 2019
  • Author : By Shreeya Nanda, Senior medwireNews Reporter

Phase II findings support further investigation of adding the PI3K inhibitor taselisib to neoadjuvant endocrine therapy for stage I–III breast cancer...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Add-On Taselisib Boosts ORR In ER-Positive Early-Stage Breast Cancer

Melanoma - Therapy - Anticancer Agents - Complications/Toxicities of Treatment

Dual BRAF–MEK Inhibition Linked To Increased CV Risk

  • 14 Aug 2019
  • Author : By Shreeya Nanda, Senior medwireNews Reporter

A meta-analysis has highlighted the potential cardiovascular risks of combination BRAF–MEK inhibitor therapy in patients with melanoma...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Dual BRAF–MEK Inhibition Linked To Increased CV Risk

Non-Small Cell Lung Cancer - Therapy - Anticancer Agents

No Benefit With Bevacizumab Addition To Erlotinib For EGFR-Mutated NSCLC

  • 13 Aug 2019
  • Author : By Lynda Williams, Senior medwireNews Reporter

Progression-free survival was comparable in patients with metastatic non-small-cell lung cancer positive for an EGFR mutation treated with erlotinib alone or in combination with bevacizumab

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof No Benefit With Bevacizumab Addition To Erlotinib For EGFR-Mutated NSCLC

Cervical Cancer - Surgical Oncology - Locoregional Treatment

Ontogenetic Cancer Field Approach Might Avoid Need For Cervical Cancer Radiotherapy

  • 12 Aug 2019
  • Author : By Lynda Williams, Senior medwireNews Reporter

Locoregional control of cervical cancer may be achieved with surgery alone based on ontogenetic cancer fields

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Ontogenetic Cancer Field Approach Might Avoid Need For Cervical Cancer Radiotherapy

Gastric Cancer - Anticancer Agents

RAINSTORM Fails To Show Ramucirumab Advantages For East Asian Gastric Cancer Patients

  • 07 Aug 2019
  • Author : By Lynda Williams, Senior medwireNews Reporter

The addition of ramucirumab to S-1 plus oxaliplatin therapy did not improve the outcome of East Asian patients with treatment-naïve, advanced gastric cancer...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof RAINSTORM Fails To Show Ramucirumab Advantages For East Asian Gastric Cancer Patients

Non-Small Cell Lung Cancer - Radiation Oncology

Natural Disasters Impact NSCLC Radiotherapy Success

  • 18 Jul 2019
  • Author : By Lynda Williams, Senior medwireNews Reporter

Disruption of radiotherapy by hurricanes results in poorer non-small-cell lung cancer survival...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Natural Disasters Impact NSCLC Radiotherapy Success

Gastric Cancer - Urothelial Cancers - Non-Small Cell Lung Cancer - Clinical Research - Anticancer Agents - Immunotherapy

JVDF Trial Results Reported For Ramucirumab Plus Pembrolizumab

  • 16 Jul 2019
  • Author : By Lynda Williams, Senior medwireNews Reporter

A combination of VEGFR-2 and PD-1 inhibitors is well tolerated by patients with advanced gastric or gastro-oesophageal junction adenocarcinoma, non-small-cell lung cancer or urothelial carcinoma...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page...

view detailsof JVDF Trial Results Reported For Ramucirumab Plus Pembrolizumab

Anticancer Agents - Bioethics, Legal, and Economic Issues

OS Benefit Not Found For Majority Of Novel Oncology Indications After US FDA Approval

  • 09 Jul 2019
  • Author : By Lynda Williams, Senior medwireNews Reporter

Almost two-thirds of novel oncology drug indications do not achieve an overall survival or patient-reported outcome benefit...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof OS Benefit Not Found For Majority Of Novel Oncology Indications After US FDA Approval

Non-Small Cell Lung Cancer - Immunotherapy

Corticosteroid Link To NSCLC Immunotherapy Response Challenged

  • 25 Jun 2019
  • Author : By Lynda Williams, Senior medwireNews Reporter

US researchers dispute the hypothesis that use of corticosteroids may hamper non-small-cell lung cancer response to immunotherapy...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Corticosteroid Link To NSCLC Immunotherapy Response Challenged

Breast Cancer - Ovarian Cancer - Clinical Research - Anticancer Agents - Immunotherapy

Niraparib Plus Pembrolizumab ‘Promising’ For Advanced TNBC, Ovarian Cancer

  • 20 Jun 2019
  • Author : By Lynda Williams, Senior medwireNews Reporter

Patients with advanced triple-negative breast cancer and recurrent ovarian cancer have responded to treatment with the PARP inhibitor niraparib given alongside the PD-1 inhibitor pembrolizumab...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Niraparib Plus Pembrolizumab ‘Promising’ For Advanced TNBC, Ovarian Cancer

Non-Small Cell Lung Cancer - Anticancer Agents

Gefitinib–Chemotherapy Boosts Advanced EGFR-Mutated NSCLC Survival

  • 10 Jun 2019

Combining first-line gefitinib with pemetrexed and carboplatin significantly improves the outcome of advanced non-small-cell lung cancer patients with an activating EGFR mutation...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Gefitinib–Chemotherapy Boosts Advanced EGFR-Mutated NSCLC Survival

Breast Cancer - Anticancer Agents

MONALEESA-7: Ribociclib Delivers OS Benefit For Premenopausal Advanced Breast Cancer

  • 07 Jun 2019
  • Author : By Lynda Williams, Senior medwireNews Reporter

Premenopausal women with advanced hormone-receptor positive, HER2-negative breast cancer derive a significant overall survival benefit from the addition of ribociclib to endocrine therapy...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof MONALEESA-7: Ribociclib Delivers OS Benefit For Premenopausal Advanced Breast Cancer

Head and Neck Cancers - Anticancer Agents - Radiation Oncology

Induction Chemotherapy Boosts Nasopharyngeal Carcinoma Response

  • 03 Jun 2019
  • Author : By Lynda Williams, Senior medwireNews Reporter

Use of induction chemotherapy significantly improves survival for patients undergoing chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Induction Chemotherapy Boosts Nasopharyngeal Carcinoma Response

Prostate Cancer - Anticancer Agents

Darolutamide QoL Benefit Demonstrated For Nonmetastatic CRPC

  • 01 Jun 2019
  • Author : By Lynda Williams, Senior medwireNews Reporter

Results from the ARAMIS trial of men with castration-resistant prostate cancer indicate darolutamide fends off pain progression and quality of life deterioration, as well as metastases, compared with placebo...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Darolutamide QoL Benefit Demonstrated For Nonmetastatic CRPC